• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Philippines Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Philippines Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Philippines
  • 103 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Monitor
  • Local Companies
  • MediChem Pharmaceuticals
  • Merck & Co
  • Multinational Companies
  • Novartis
  • MORE

BMI View: BMI has revised up its forecast for the Philippines' pharmaceutical market following reassessment of the country's macroeconomic conditions. According to BMI's Country Risk team, the Philippine economy expanded by an impressive 5.9% year-on-year in Q212 due to strong growth from various sectors, such as services and exports. Consequently, we have upgraded the pharmaceutical market forecast. We continue to hold our view that pharmaceutical firms will see short-term opportunities in the Philippines due to ineffective governance of the prices of drugs.

Headline Expenditure Projections

- Pharmaceuticals: PHP126.04bn (US$2.91bn) in total sales in 2011, rising to PHP129.96bn
(US$2.89bn) in 2012; +3.1% in local currency terms and +3.3% in US dollar terms. Forecast up slightly from Q412 due to improved macroeconomic outlook.

- Healthcare: PHP364.95bn (US$8.43bn) in sales in 2011 rising to PHP408.26bn (US$9.45bn) in 2012; +11.9% in local currency terms and +12.1% in US dollar terms. Forecast up slightly from Q412 due to improved macroeconomic outlook.

- Medical devices: PHP14.12bn (US$297mn) in sales in 2011 rising to PHP15.11bn (US$350mn)
in 2012; READ MORE >

Executive Summary 5

SWOT Analysis 7

Philippines Pharmaceutical And Healthcare Industry SWOT 7

Philippines Political SWOT 8

Philippines Economic SWOT 9

Philippines Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q113 11

Rewards 12

Risks 12

The Philippines - Market Summary 14

Regulatory Regime 15
Table: History Of Food And Drugs Administration 15

Regional Cooperation 17

Cheaper Medicines Legislation 17

Intellectual Property Regime 18

IP Shortcomings 19

IP Disputes 20

Counterfeit Drugs 21

Pricing Regime 22

Pricing Developments 24
Table: Medicines Subject To March 31 2010 Government Mediated Access Price 25

Reimbursement Regime 26

International Cooperation 26

Industry Trends and Developments 28

Epidemiology 28

Communicable Diseases 30

Healthcare Sector 31

Health Insurance 35

Recent Health Insurance Developments 36

Healthcare Sector Financing 36

Medical Tourism 37

Biotechnology and Research 38

Biotechnology Developments 39

Traditional Medicines 40

Medical Devices 40

Industry Forecast Scenario 42

Overall Market Forecast 42
Table: Pharmaceutical Sales Indicators 2008-2016 43

Healthcare Market Forecast 44
Table: Healthcare Expenditure Indicators 2008-2016 45
Table: Healthcare Governmental Indicators 2008-2016 45
Table: Healthcare Private Indicators 2008-2016 46

Key Growth Factors - Macroeconomic 47
Table: Philippines - Economic Activity 52

Prescription Drug Market Forecast 53
Table: Prescription Drug Sales Indicators 2008-2016 54

Patented Drug Market Forecast 55
Table: Patented Drug Market Indicators 2008-2016 56

Generic Drug Market Forecast 57
Table: Generic Drug Sales Indicators 2008-2016 59

OTC Medicine Market Forecast 60
Table: OTC Medicine Sales Indicators 2008-2016 61

Pharmaceutical Trade Forecast 62
Table: Exports and Imports Indicators 2008-2016 64

Medical Device Market Forecast 65
Table: Medical Devices Sales Indicators 2008-2016 66

Other Healthcare Data Forecasts 67

Key Risks To BMI's Forecast Scenario 67

Competitive Landscape 69

Pharmaceutical Industry 69
Table: Pharmaceutical Industry Overview 69

Domestic Pharmaceutical Industry 69

Recent Pharmaceutical Industry Developments 71

Pharmaceutical Distribution and Retail 71

Distribution 72

Retail 73
Table: Overview Of BnB, BNB and P100 Programme 75
Table: Cost Of Generic Drugs In Philippines (PHP) 76
Table: Number Of BnBs and BNBs In Selected Philippine Regions 76

Company Monitor 77

Local Companies 77

Unilab 77

Pascual Laboratories 79

Pacific Pharma Generics 81

MediChem Pharmaceuticals 82

Multinational Companies 83

GlaxoSmithKline Philippines 83

Pfizer 85

Novartis 87

Merck & Co 90

Sanofi 91

Demographic Outlook 93
Table: Population By Age Group, 1990-2020 ('000) 94
Table: Population By Age Group, 1990-2020 (% of total) 95
Table: Key Population Ratios, 1990-2020 96
Table: Rural/Urban Population Split, 1990-2020 96

Glossary 97

BMI Methodology 99

How We Generate Our Pharmaceutical Industry Forecasts 99

Risk/Reward Ratings Methodology 00

Ratings Overview 00
Table: Pharmaceutical Business Environment Indicators 01

Weighting 02
Table: Weighting Of Components 02

Company Monitor
Local Companies
Unilab
Pascual Laboratories
Pacific Pharma Generics
MediChem Pharmaceuticals
Multinational Companies
GlaxoSmithKline Philippines
Pfizer
Novartis
Merck & Co
Sanofi

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos